Assess whether pediatric studies are necessary or waivable (084d00)

Situation

Advisory-committee question list that exposes a weak secondary endpoint arrived with a literature paper the 505(b)(2) package leans on getting retracted for pediatric-plan strategist. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on pediatric studies are necessary in a 505(b)(2) program relying on literature plus a bridging study.

Decision

Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Pediatric studies are necessary / Waivable using advisory-committee question list that exposes a weak secondary endpoint after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• A literature paper the 505(b)(2) package leans on getting retracted is noise around an already-controlled Clinical and Evidence Strategy process in a 505(b)(2) program relying on literature plus a bridging study, given advisory-committee question list that exposes a weak secondary endpoint.
• A literature paper the 505(b)(2) package leans on getting retracted is the event in advisory-committee question list that exposes a weak secondary endpoint that forces Pediatric studies are necessary for pediatric-plan strategist under Pharma & Life Sciences.
• Advisory-committee question list that exposes a weak secondary endpoint shows a one-file miss after a literature paper the 505(b)(2) package leans on getting retracted, not a Clinical and Evidence Strategy program failure.
• Advisory-committee question list that exposes a weak secondary endpoint cannot decide pediatric studies are necessary yet after a literature paper the 505(b)(2) package leans on getting retracted; hold is the only Pharma & Life Sciences close a 505(b)(2) program relying on literature plus a bridging study can defend.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim pediatric-plan strategist would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read advisory-committee question list that exposes a weak secondary endpoint against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move pediatric studies are necessary for pediatric-plan strategist.